Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HTN Clear all
Recruiting Not applicable Interventional

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638
View directory record Official record
Conditions
Hypertension, Hypertension, Systolic, Hypertension, Essential
Interventions
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
72
States / cities
Scottsdale, Arizona • Glendale, California • Newport Beach, California + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Recruiting No phase listed Observational

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

NCT06933836
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
DSLT enables newly diagnosed patients to remain well controlled and off medications
Device
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
30 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Nov 10, 2026, 2:59 PM EST
Completed No phase listed Observational

Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices

NCT01430936
View directory record Official record
Conditions
Cardiac Decompensation
Interventions
Not listed
Lead sponsor
Aventyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Mineola, New York • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Nov 10, 2026, 2:59 PM EST
Recruiting Phase 2 Interventional

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of Pregnancy

NCT07238400
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone 100 mg daily, Chlorthalidone 25 mg daily, Potassium Placebo, Potassium Chloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 4 Interventional Results available

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

NCT00669279
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Nov 10, 2026, 2:59 PM EST
Completed Not applicable Interventional

Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative

NCT06831162
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Hyperlipidemia, Health-related Social Problems
Interventions
Multi-level HRSN initiative
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6,928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Active, not recruiting Not applicable Interventional

Investigating Behavior Change Methods for the Management of Hypertension

NCT07631546
View directory record Official record
Conditions
Hypertension
Interventions
Digital Coaching Plan, Health Awareness
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Withdrawn No phase listed Observational

Validation of Pulsewave Blood Pressure Monitor in Hypertensive and Normotensive Pregnant and Postpartum Women

NCT02823873
View directory record Official record
Conditions
Hypertension
Interventions
Pulsewave oscillometric wrist cuff blood pressure monitor
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Nov 10, 2026, 2:59 PM EST
Completed Not applicable Interventional

Mechanisms of Intradialytic Hypertension

NCT01947673
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis, Haemodialysis-induced Symptom, Hypertension
Interventions
Mindfulness Meditation, Health Education
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

NCT00963027
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Esomeprazole
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Nov 10, 2026, 2:59 PM EST
Completed Not applicable Interventional

Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease

NCT01900470
View directory record Official record
Conditions
Obesity, Diabetes, Hypertension, Asthma/COPD With Tobacco Dependence
Interventions
CHW Goal Support
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Nov 10, 2026, 2:59 PM EST
Recruiting Not applicable Interventional

WEARABLE-BP: Wearable Everyday Automated Readings to Enable Assessment of Blood Pressure Control

NCT07523269
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Aktiia G1 BP monitor for 12 months, Traditional BP monitor for 6 months / Aktiia G1 BP monitor for 6 months
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
21 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

NCT05129345
View directory record Official record
Conditions
Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Charlotte, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Terminated Not applicable Interventional Results available

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

NCT02928289
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 10, 2026, 2:59 PM EST
Recruiting Not applicable Interventional

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT07214376
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions
Pulmonary Artery Denervation (PADN), Sham procedure control
Device
Lead sponsor
Pulnovo Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
15
States / cities
Tucson, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 2:59 PM EST
Withdrawn Not applicable Interventional

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NCT02958358
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Robert Scott Harris, M.D.
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Nov 10, 2026, 2:59 PM EST
Withdrawn Phase 2 Interventional

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

NCT02108743
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension.
Interventions
Albuterol., Normal saline placebo
Drug
Lead sponsor
American Medical Association Foundation
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 1Phase 2 Interventional Results available

Intravenous Norepinephrine for Orthostatic Hypotension

NCT01285908
View directory record Official record
Conditions
Orthostatic Hypertension
Interventions
Intravenous Norepinephrine Infusion
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Nov 10, 2026, 2:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

NCT01712126
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan and Hydrochlorothiazide, Avalide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 2 Interventional Results available

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

NCT03554291
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right Heart Failure
Interventions
Famotidine 20 MG, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Nov 10, 2026, 2:59 PM EST
Completed Not applicable Interventional

Early Identification and Action in CKD

NCT02208674
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Protocolized, pharmacist-delivered CKD Action Plan
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 3 Interventional

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients

NCT00409643
View directory record Official record
Conditions
Hypertension
Interventions
valsartan+amlodipine combination, valsartan, amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 2 Interventional

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

NCT06249152
View directory record Official record
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
Interventions
QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Nov 10, 2026, 2:59 PM EST
Completed Phase 4 Interventional Results available

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

NCT02133352
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Nov 10, 2026, 2:59 PM EST